Abstracts Archive

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of aggressive lymphomas. Primary nodal subtypes: PTCL-not otherwise specified, angioimmunoblastic TCL (AITL), and anaplastic large cell lymphoma. WHO classification of lymphoid neoplasms now groups AITL, PTCL-NOS with TFH phenotype, a...

IntroductionT-cell lymphoma patient outcome remains largely unsatisfactory. To identify active therapies, we screened 474 compounds as single agents and in combination with the pan-HDAC inhibitor belinostat in four TCL cell lines.Methods Cells were exposed to 0.5µM library compound, belin...

IntroductionAnti-PD1 immunotherapy has shown encouraging albeit modest efficacy in relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) and NK/T-cell lymphoma (NKTL), achieving response rates of approximately 30% and 60%, respectively. Recent studies suggest that PARP inhibitors in tandem with ...

Background:Cutaneous T-cell lymphoma (CTCL) is a rare, incurable non-Hodgkin lymphoma characterized by immune dysregulation and chronic skin inflammation. Interferon-α has demonstrated activity in CTCL with response rates of 30–80%, but its use is limited by short half-life, frequent dosing, and ...

IntroductionPeripheral T-cell lymphomas (PTCL) are a group of aggressive lymphomas. Duvelisib is an oral dual inhibitor of phosphatidylinositol 3-kinase-δ/γ, with activity in PTCL. The duvelisib dosing regimen in PTCL was established in PRIMO (NCT03372057), a phase 2, open-label, single-arm study....

Introduction: Extranodal NK/T-cell lymphoma (ENKTL), nasal type, is typically treated with chemoradiotherapy but often causes significant toxicity. PD-1 inhibitors, pembrolizumab and tislelizumab, have shown efficacy in relapsed or refractory ENKTL, although responses may vary with the tumor microen...

Introduction and Objectives: The relationship between PD-L1 expression and treatment outcomes in ENKTL remains poorly defined. This study (NCT04414163) aimed to explore PD-L1 expression and its association with clinical response to danburstotug. Methods: Patients received danburstotug (20 mg/kg...

Large granular lymphocytic leukemia (LGLL), a chronic, lymphoproliferative disorder of cytotoxic T (CD8) and natural killer (NK) cells, leads to neutropenia, recurrent infections, and anemia. No approved therapies exist; chronic immunosuppression makes long-term management challenging. DR-01 is a n...

Mogamulizumab is approved in the United States (US) for the treatment of adults with relapsed/refractory mycosis fungoides/Sézary syndrome (MF/SS) following ≥1 prior systemic treatment. This retrospective, observational cohort study used ConcertAI electronic medical records to investigate effecti...